Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

一、 日常经营合同概况 2024 年 4 月 3 日，博济医药科技股份有限公司（以下简称"博济医药"、"公 司"、"乙方"）与广州瑞安博医药科技有限公司（以下简称"广州瑞安博"、"甲 方"）签订了《技术服务（委托）合同》，合同总金额为人民币 6,963 万元（含税）。 合同约定广州瑞安博委托博济医药组织开展"AR882 胶囊"治疗原发性痛风伴 高尿酸血症患者的Ⅱ/Ⅲ期临床试验研究服务。具体内容详见公司于 2024 年 4 月 8 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司签订日常经营合同的 自愿性披露公告》（公告编号：2024-029）。 证券代码：300404 证券简称：博济医药 公告编号：2025-083 博济医药科技股份有限公司 关于日常经营合同的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、 交易进展情况 该项目执行过程中，因项目情况变化，经双方友好协商，双方签订了《"化 药 1 类新药 AR882 胶囊Ⅱ/Ⅲ期临床试验技术服务（委托）合同"补充协议》（以 下简称"《补充协议》"），对原合同部分内容进行变更，并 ...

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the development paths of innovative drugs and the role of AI in drug research and development [1][2] - Industry experts emphasized the need for Chinese pharmaceutical companies to shift from "follower" to "leader" by addressing unmet medical needs and leveraging innovative technologies [1][2] Group 1: Conference Highlights - The conference theme was "Bay Area Innovation, Navigating New Journeys," discussing key topics such as dual circulation development, accelerated technology transfer, and compliance in global expansion [1] - Notable speakers included industry leaders and experts, highlighting the importance of innovation and internationalization as core drivers for Chinese pharmaceutical companies [2] Group 2: Regulatory and Industry Perspectives - The Director of the Guangdong Provincial Drug Administration stressed the importance of drug quality and safety, urging companies to strengthen regulatory compliance and communication with authorities to avoid approval delays [1] - The conference aimed to inject new vitality into the biopharmaceutical industry in the Greater Bay Area and across China, promoting high-quality development and attracting talent and projects [1]

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the theme "Bay Area Innovation, Navigating New Journeys" [1] - Key topics discussed included the dual circulation development path for innovative drugs, acceleration of technology transfer, compliant global expansion, and the role of AI in empowering the entire drug development chain [1] Group 1 - The conference was co-hosted by the Guangdong Provincial Biopharmaceutical Innovation Technology Association and the Guangzhou Science and Technology Progress Foundation, with participation from various organizations including Boji Pharmaceutical Technology Co., Ltd. [1] - The event aimed to explore solutions for innovative drugs in the current complex environment, injecting new vitality and wisdom into the innovation development of the biopharmaceutical industry in the Greater Bay Area and nationwide [1] Group 2 - Notable attendees included prominent figures such as academician Zhong Nanshan, various directors from health authorities in Guangdong, Hong Kong, and Macau, and leaders from over 1,000 top scientists and industry leaders [2] - The conference provided a platform for discussing the future development and innovative practices in the biopharmaceutical sector within the Greater Bay Area [2]

Core Viewpoint - Nanjing Haina Pharmaceutical Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, following a previous unsuccessful attempt for an A-share IPO due to the withdrawal of its sponsor [1][2] Financial Performance - Haina Pharmaceutical has shown steady revenue growth from 2022 to 2024, with revenues of 265 million, 409.6 million, and 424.6 million RMB respectively, but net profit has declined by 27% in 2024 [2][3] - For the first half of 2025, the company reported revenues of 178 million RMB and a net profit of 22.08 million RMB, representing declines of 16.97% and 25.82% year-on-year [2][3] - The gross profit margin has decreased from 60.1% in 2022 to 46.0% in 2024, although it rebounded to 52.1% in the first half of 2025 [3] Business Model and Services - Haina Pharmaceutical operates a unique "CXO + MAH" business model, focusing on both contract research organization (CRO) services and proprietary product pipelines [4][5] - The majority of revenue comes from CXO services, accounting for 65% in 2022 and increasing to 87.8% in 2024 [5] - The company has signed 67 drug technology transfer agreements, indicating a proactive approach to commercialization [5] Market Position and Industry Context - The CXO industry is experiencing growth, with the outsourcing expenditure in the pharmaceutical sector expected to rise from 47.8% in 2024 to 61.0% by 2029 [8] - Haina Pharmaceutical ranks second in China for the number of approved clinical trials and marketing licenses among CXO service providers [11] - Despite growth potential, the company faces challenges due to its focus on generic drugs, which have lower technical barriers compared to innovative drugs [11][12] Financial Health and Risks - The company has experienced negative cash flow from operating activities in 2024 and the first half of 2025, indicating potential financial strain [6] - Accounts receivable have increased significantly, leading to longer collection periods, which may pose risks to cash flow [7] - The competitive landscape for generic drugs is pressured by national procurement policies, impacting pricing and profitability [12]

Core Viewpoint - Nanjing Haina Pharmaceutical Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, following a previous unsuccessful attempt for an A-share IPO due to the withdrawal of its sponsor [1] Financial Performance - Haina Pharmaceutical has experienced a decline in both revenue and net profit in the first half of 2025, with revenue of 178 million yuan and net profit of 22.08 million yuan, representing decreases of 16.97% and 25.82% year-on-year, respectively [2][3] - The company's revenue from 2022 to 2024 showed steady growth, with figures of 265 million yuan, 410 million yuan, and 425 million yuan, but net profit fell by 27% in 2024 [2][3] - The overall gross margin decreased from 60.1% in 2022 to 46.0% in 2024, although it rebounded to 52.1% in the first half of 2025 [3] Business Model and Services - Haina Pharmaceutical operates a unique "CXO + MAH" business model, focusing on both contract research organization (CRO) services and proprietary product pipelines, primarily in chemical generics and improved innovative drugs [4][5] - The company has a comprehensive CXO platform covering the entire drug development process, with 398 ongoing CXO projects as of mid-2025 [5] Market Position and Challenges - Haina Pharmaceutical ranks second in China for the number of approved clinical trials and marketing licenses among CXO service providers, but its focus on generics places it at a competitive disadvantage compared to peers specializing in innovative drugs [11] - The domestic CXO industry is fragmented, with major players facing pressures from national procurement policies, leading to significant revenue declines for competitors [12] Industry Outlook - The CXO industry is expected to grow, with the outsourcing expenditure in the pharmaceutical sector projected to rise from 36.8% in 2020 to 66.0% by 2034 [8] - Despite facing short-term performance pressures, Haina Pharmaceutical's unique business model and full-chain service capabilities may provide competitive advantages in a challenging market [12]

Core Insights - Boji Pharmaceutical's stock price increased by 2.19% on November 13, reaching 10.74 CNY per share, with a total market capitalization of 4.143 billion CNY [1] - The company has seen a year-to-date stock price increase of 23.19%, with a 7.51% rise over the last five trading days [1] Financial Performance - For the period from January to September 2025, Boji Pharmaceutical reported a revenue of 584 million CNY, representing a year-on-year growth of 5.06% [2] - The net profit attributable to shareholders was 21.9139 million CNY, which reflects a significant decrease of 49.36% compared to the previous year [2] Business Overview - Boji Pharmaceutical specializes in providing preclinical research services, clinical research services, technology transfer services, and consulting services related to new drug development [1] - The revenue composition of the company includes 80.18% from clinical research services, 11.31% from preclinical research services, 6.50% from other consulting services, and 2.02% from supplementary services [1] Shareholder Information - As of September 30, the number of shareholders for Boji Pharmaceutical was 29,600, an increase of 18.91% from the previous period [2] - The average number of circulating shares per shareholder decreased by 15.21% to 9,497 shares [2] Dividend Information - Since its A-share listing, Boji Pharmaceutical has distributed a total of 27.7583 million CNY in dividends, with 12.0783 million CNY distributed over the last three years [3]

Monetary Policy and Economic Outlook - The People's Bank of China released the monetary policy execution report for Q3 2025, indicating that the domestic economic recovery needs further consolidation. The central bank plans to deepen financial reforms and enhance high-level opening-up, aiming to build a robust monetary policy system and a comprehensive macro-prudential management framework [1][2]. Manufacturing and Infrastructure Development - The Ministry of Industry and Information Technology issued a notice to accelerate the systematic layout and high-level construction of manufacturing pilot platforms, targeting the establishment of a modern pilot platform system by the end of 2027 [1][3]. - The National Development and Reform Commission announced that the infrastructure real estate investment trusts (REITs) will enter a normalized issuance phase in 2024, with 105 projects recommended to the China Securities Regulatory Commission, totaling 207 billion yuan in funds, expected to drive over 1 trillion yuan in new project investments [3]. New Energy Vehicle Industry - The Chinese automotive industry reported record growth in the new energy vehicle sector, with October 2025 seeing monthly new car sales of new energy vehicles surpassing 50% of total new car sales for the first time [1][3]. Chemical Industry Insights - Seven chemical-themed funds have been reported since Q3, with a focus on the chemical sector's supply-side changes, including stricter approvals for new capacities. The industry is expected to see a recovery in profitability and valuation [11]. Battery and Renewable Energy Sector - The 12th China (Suzhou) Battery New Energy Industry International Summit highlighted China's competitive advantage in the lithium battery sector, with over 90% of global shipments in energy storage lithium batteries. Future demand for lithium batteries is expected to grow, particularly in energy storage applications [7]. Pharmaceutical Logistics Development - Shanghai's new guidelines aim to enhance the development of modern pharmaceutical logistics, promoting the establishment of a high-efficiency and professional logistics system to ensure drug supply and quality [6].

分组1 - Midea Group announced a cash dividend distribution plan for the 2025 mid-term A-shares, distributing 5 yuan per 10 shares, totaling 3.448 billion yuan [1] - Huayuan Communication is planning a change in control and will suspend trading of its stock starting November 12, 2025, for up to two trading days [2] - Shangwei New Materials reported a significant stock price increase of 1573.52% from July 9 to November 11, 2025, but its new intelligent robot business is still in the development stage and has not generated revenue [3] 分组2 - Shannon Chip announced that shareholder Shenzhen Xinlianpu pledged 1.27 million shares, accounting for 5.55% of its holdings and 0.27% of the total share capital [4] - Tianji Co., Ltd. reported that its controlling shareholder pledged 39.965 million shares for its own production and operation, representing 64.79% of its holdings and 7.97% of the total share capital [5] - ST Zhengping completed its stock trading situation review and will resume trading on November 12, 2025, with no significant changes in its production and operation [6] 分组3 - Furi Co. reported that its subsidiary Furi New Energy is facing risks of losses despite a 47.78% year-on-year increase in revenue to 168.3981 million yuan for the first three quarters of 2025 [7] - Wentai Technology announced that major shareholders reduced their holdings by 12.4443 million shares, completing the reduction plan [8] 分组4 - Anke Biotech signed a framework agreement for exclusive agency of PA3-17 injection, a CAR-T cell therapy product, in Greater China [9] - Tongxing Technology plans to invest approximately 3.2 billion yuan in a project to produce 100,000 tons of sodium-ion battery cathode materials and 6 GWh of battery cells [10] - Redik plans to establish a joint venture for the development of robotic components, with a registered capital of 100 million yuan [11] 分组5 - Haike New Source signed a strategic cooperation agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent over three years [12] - World announced that its diamond micro-drill products for PCB processing are still in the R&D phase and have not generated revenue [13] 分组6 - Xiamen Airport reported a 1.56% year-on-year increase in passenger throughput for October [14] - New City Holdings reported a 7.65% year-on-year increase in total commercial operating revenue for October [15] - Huadong Holdings announced a 0.65% year-on-year decrease in pig sales revenue for October [15] 分组7 - Keykai Technology's controlling shareholder plans to transfer 3% of its shares [15] - Zhongyou Engineering won a joint bid for a project worth approximately 3 billion yuan in Kazakhstan [15] - Weiteng Electric plans to raise no more than 300 million yuan through a private placement for smart manufacturing projects [15]